NEI Podcast

When it comes to serious mental illness (SMI), mental health professionals work hard to help remove the associated negative stigma, and to educate patients and caregivers to help them thrive. In this episode, we interview two clinical experts who are part of an interdisciplinary team at the APA/SMI Advisor program. This joint initiative between the American Psychiatric Association and the Substance Abuse and Mental Health Services Administration, or SAMSHA is an innovative clinical support program for clinicians, caregivers, and patients with serious mental illness.  In this episode, we discuss the topic of serious mental illness with two mental health experts, Dr. Donna Rolin and Dr. Joseph Ventura. We also discuss their upcoming joint-presentation at this year’s APNA, on the importance of incorporating the Basic Psychiatric Rating Scale (BPRS) into practice.   Donna Rolin, Ph.D. is Clinical Associate Professor and the Director of the Psychiatric Mental Health Nurse Practitioner program at the University of Texas with 23 years of experience in psychiatric nursing. She is co-leading inter-disciplinary graduate training initiatives with Schools of Nursing, Medicine, Educational Psychology, Social Work, and Pharmacy with funding from the Health Resources and Services Administration and the Texas Higher Education Coordinating Board aiming to expand a culturally diverse workforce for underserved populations. She serves as the Co-Director of the Institute for Domestic Violence and Sexual Assault (IDVSA), working alongside Schools of Social Work, Law and Bureau of Business Research. Dr. Rolin’s current research focuses on wellness self-management for mental health promotion and the integration of telepresence robots in healthcare education. Dr. Rolin serves on the national Board of Directors of the American Psychiatric Nurses Association and the local Board of the Directors of the Psychiatric Advanced Practice Nurses of Austin. Dr. Rolin continues her clinical practice as a Psychiatric Advanced Practice Registered Nurse with a community-based group working with underserved patients with serious mental illnesses (SMI), neurocognitive disorders, and intellectual disabilities in outpatient, long term care, telepsychiatry, and inpatient psychiatric facilities. She acts as the SMI Nursing Expert on the American Psychiatric Association’s Clinical Support Services for SMI (CSS-SMI) Clinical Expert Team. Joseph Ventura, Ph.D. is a Clinical Psychologist and Research Scientist with expertise in the assessment and treatment of individuals with serious mental illness. Dr. Ventura is the Director of Cognitive Training and Diagnosis and Symptom Assessment for the UCLA Aftercare Program. His areas of expertise include cognitive remediation, assessment of neurocognitive functioning, psychiatric diagnosis, symptom assessment, recovery from mental illness, and evaluation of functional outcomes in the early phase of schizophrenia. Dr. Ventura has led research funded by several agencies most notably the National Institute of Mental Health (NIMH) and the Brain and Behavior Foundation (formerly NARSAD). His research has concentrated on stressful life events, positive and negative symptoms, neurocognition, social cognition, cognitive training, and predictors of course and functional outcome. Dr. Ventura has played a major role in the development and publication of methods for standardizing diagnostic and symptom assessment training and for ongoing quality assurance. His recent work focuses on clinical correlates of the core features of serious mental illness, dimensions of social cognition, inflammatory biomarkers, the development of interview-based assessments of cognitive functioning, and factors that are associated with recovery from serious mental illness. Recently, he was awarded a US Fulbright Scholar Grant to develop a program promoting early assessment, identification, and prevention of mental illness in clinical high-risk populations in North Africa. Dr. Ventura has published widely in peer-reviewed journals, lectured extensively, and conducted numerous training workshops both nationally and internationally. UCLA Aftercare Program: The UCLA Aftercare Program (brochure attached) is a joint clinical and research program located in the UCLA Department of Psychiatry specializing in the treatment of people who are in the early phase of schizophrenia or a related psychotic disorder. For over 30 years, and through NIMH and industry funding, our Aftercare treatment team has been providing comprehensive services to schizophrenia patients most of whom are transitional age youth (late teens or early twenties). However, we can serve patients from age 18 to 45. Our primary treatment aim is to assist patients with symptomatic and functional recovery after experiencing a first psychotic episode or who are within 2 years of the first onset of psychotic symptoms.  The Aftercare program provides a comprehensive set of treatment services to eligible patients including regular visits with a psychiatrist, anti-psychotic medication (second generation), case management, various forms of psychosocial interventions including group and individual therapy, a cognitive training program that is in some cases boosted by an aerobic exercise program, family education and support, and transportation to UCLA. Our clinic psychiatrists are Laurie Casaus, M.D. and Margaret Distler, M.D. Additional Aftercare services include, supported employment and supported education programs, family therapy, and providing research updates to family members. We can provide all of these services for up to two years at no cost to the patient or family because we are funded.   The Aftercare clinic is headed by members of the UCLA Department of Psychiatry, Keith Nuechterlein, Ph.D., Kenneth Subotnik, Ph.D., Luana Turner, PsyD., Joseph Ventura, Ph.D, who have been providing these services through the Aftercare Program for many years to early course patients. Rebecca Zornitsky, MSc. is our Community Liaison Specialist along with Taylor Jester and Elaine Clarke. APA/SMI Adviser Site & Resources: https://smiadviser.org/ Clozapine Center of Excellence: https://smiadviser.org/about/clozapine Long-Acting Injectable (LAI) Antipsychotics Center of Excellence: https://smiadviser.org/about/lai How to download SMI Adviser App: Apple: https://apps.apple.com/us/app/smi-adviser/id1473024646 Google: https://play.google.com/store/apps/details?id=org.smiadviser&hl=es_PE How to download My Mental Health Crisis Plan (Psychiatric Advance Directive [PAD]) App Apple: https://apps.apple.com/us/app/my-mental-health-crisis-plan/id1497373282 Google: https://play.google.com/store/apps/details?id=org.smiadviser.apa&hl=en_US APNA Annual Meeting Presentation on Brief Psychiatric Rating Scale (BPRS) Annual Meeting 9/30 – 10/4/2020 (Virtual) https://www.apna.org/i4a/pages/index.cfm?pageid=3467 Presentation on BPRS – Dr. Joseph Ventura & Dr. Donna Rolin Thursday, 10/1 @5pm ET https://www.apna.org/i4a/pages/index.cfm?pageID=4595 2034: Advanced Practice 5:00pm ET - 5:45pm ET Using the Brief Psychiatric Rating Scale (BPRS) as a Symptom Assessment Tool in Measurement-Based Care – RN, APRN This interactive presentation teaches participants to rate psychiatric symptoms using a structured interview, the Brief Psychiatric Rating Scale. The goal is to build and/or expand assessment skills for rating initial symptom severity and for monitoring symptom change over time to improve quality of treatment within a measurement-based care approach.  Abstract Presenters: Joseph Ventura, PhD; Donna Rolin, PhD, APRN, PMHCNS-BC, PMHNP-BC  

Autism Spectrum Disorder (ASD) is highly comorbid with other psychiatric disorders, including attention deficit hyperactivity disorder (ADHD). Unfortunately, there may be many overlapping symptoms between ASD and ADHD that make it difficult to distinguish between these disorders. In this fascinating episode, Dr. David Goodman examines the history of autism, Asperger’s disorder, and how to differentiate between overlapping symptoms for ADHD. He also addresses how to treat these disorders concurrently. Dr. David W. Goodman is an assistant professor in the department of psychiatry and behavioral sciences at Johns Hopkins School of Medicine in Baltimore, and the director and founder of the Adult Attention Deficit Disorder Center of Maryland in Baltimore, MD. His interests include adult ADHD, associated mood/anxiety/substance use disorders, and complex psychopharmacology.

What specific issues do female nurse practitioners, or physicians treating mental health face in the workplace? What are some of the work-life issues that women face, when it comes to balancing a career in medicine with family? What are the research findings on sexual harassment toward women in the mental health profession? In this important episode, Dr. Christina Girgis addresses these questions, and more! Dr. Christina Girgis is a psychiatrist in the Hines, Illinois area, certified by both the American Board of Psychiatry and Neurology and the American Board of Addiction Medicine. She is currently the Medical Director of the Consultation-Liaison Psychiatry Service at Edward Hines, Jr. VA Hospital and the Associate Training Director of the Psychiatry Residency Program at Loyola University Medical Center. She is also the founder of Psychiatry Network, and several other professional Facebook groups. For more information please click on the link below: https://www.facebook.com/groups/psychnetwork/

Schizophrenia is a chronic and debilitating disorder that creates a substantial burden not only for patients but also for their families. The high rates of treatment resistance, relapse rates, and incidence of adverse side effects in patients with schizophrenia suggest that a major treatment gap continues to exist. Given the high rates of treatment resistance, novel strategies and therapeutic approaches beyond D2 receptor blockade are being intensively studied. What are some of these novel approaches? How effective are they in the treatment of schizophrenia? What medications are available, or emerging that target neurotransmitters systems beyond dopamine? In this podcast episode, Dr. Jonathan Meyer and Dr. Leslie Citrome discuss some of the ground-breaking work in this field, and how you can better treat patients with schizophrenia. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE. Learning Objectives: After completing this educational activity, you should be better able to: Describe clinical advances in our understanding of schizophrenia Describe novel treatments for schizophrenia Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.  Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.75 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Interviewer / Author Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee / Author Leslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: Acadia, Alkermes, Allergan, Avanir, BioXcel, Eisai, Impel, Indivior, Intra-Cellular Therapies, Janssen, Lundbeck, Luye, Merck, Neurocrine, Noven, Osmotica, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva, Vanda Speakers Bureau: Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Lilly, Johnson & Johnson, Merck, Pfizer Interviewee / Author Jonathan M. Meyer, MD Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Consultant/Advisor: Acadia, Alkermes, Allergan, Intra-Cellular Therapies, Neurocrine Speakers Bureau: Acadia, Alkermes, Allergan, Janssen, Neurocrine, Otsuka, Sunovion, Teva Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout. Support: This activity is supported by an unrestricted educational grant from Intra-Cellular Therapies. Released: July 23, 2020          CME credit expires: July 23, 2023

What are some of the difficulties that Muslim Americans face today, and what was the reason behind the creation of the Muslim Wellness Foundation? How does stigma about mental health problems uniquely impact the Muslim American community? What are some of the psychosocial issues and challenges that Black Muslim American's experience?  In this important and timely episode, psychiatrist Dr. Mona Masood answers these questions and so much more! As a member of the Board of Directors at the Muslim Wellness Foundation, Dr. Masood offers resources, shares exciting programs and ways to get involved with this movement.    For more information on the Muslim Wellness Foundation click on the link below:  https://www.muslimwellness.com/

The years 2019-2020 brought to us coronavirus disease 2019 (COVID-19), resulting in an unprecedented global pandemic. Emerging data, historical studies, and expert opinion point to a tremendous impact of COVID-19 on the development and exacerbation of psychiatric issues. This issue is compounded by the fact that access to mental health care services may be limited during this time of crisis. There is a critical need for mental health care providers to be prepared and educated to best serve the psychiatric needs of patients affected, either directly or indirectly, by the COVID-19 pandemic. There are still many questions. What are the psychological consequences of so many people losing their jobs, and so many businesses shutting down? What are some healthy coping strategies for parents to model at home, to protect their children’s mental health during this pandemic? In this CME NEI podcast episode, Dr. McIntyre answers these questions, and much more.  Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE.  Learning Objectives: After completing this educational activity, you should be better able to: Discuss the psychological, economic, and sociological implications that COVID-19 has had on mental health Examine the impact of COVID-19 on a variety of mental health issues Explore existing and novel strategies for continuing mental health care during a global pandemic such as COVID-19 Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.  Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. Peer Review: The content was peer-reviewed by a PhD-PMHNP specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.  Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.  Faculty Interviewer / Author Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Faculty Interviewee / Author Roger S. McIntyre, MD, FRCPC   Professor, Departments of Psychiatry and of Pharmacology; Head, Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada Grant/Research: CIHR/GACD/Chinese National Natural Research Foundation, Stanley Medical Research Institute Consultant/Advisor: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, Takeda Speakers Bureau: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, Takeda  Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.  The Planning Committee and Peer Reviewer have no financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.  Support: This activity is supported by an unrestricted educational grant from Alkermes.  Released: July 9, 2020          CME credit expires: July 9, 2023  

What exactly is brain-derived neurotrophic factor, or BDNF? What is the relationship between neuroinflammation, BDNF, and depression? What are ways that we can naturally stimulate increases in BDNF? In this exciting interview, psychiatric nurse practitioner, Michelle Novella answers all these questions and more! Michele Novella, PMHNP-BC, PMHCNS-BC, is the owner and medical director of Star Psychiatric Healthcare, LLC, in Danbury, CT. She was educated at Fairfield University in Fairfield, CT, and received her Master's Degree in Adult Psychiatric Nursing from Yale University, graduating with high Honors. Additionally, Ms. Novella is an inductee into the Sigma Theta Tau International Honor Society and is an active member of the ANA, APNA, and CTAPRNS. She is also a past recipient of the American Cancer Society's prestigious "Excellence in Onocology" Nursing Award for the State of CT.  She is a national speaker for several pharmaceutical companies, including Takeda and Lundbeck.

Healthcare workers on the frontline, working to save patients with the COVID-19 virus, during this pandemic have been especially vulnerable to mental health consequences and trauma. In the early stages of the global shut-down, Dr. Mona Masood launched the Physician Support Line, a volunteer hotline to support physicians and healthcare providers who were on the frontlines, battling the virus, and the traumatic consequences of doing so, simultaneously. Doctors, nurses, EMTs and other health care workers have been under extremely stressful conditions, increased patient loads without necessary staffing, a lack of personal protective equipment (PPE), and overtime hours, placing them at high risk for contracting the virus themselves. Many have lost colleagues to the virus.  In this episode, learn what inspired her to create this hotline, what it has done for physicians, and how you can get involved. Dr. Mona Masood is board certified in general adult psychiatry and is an outpatient psychiatrist in the Ivyland, Pennsylvania area.  She is also the founder of the Physician Support Line and a Board Member of the nonprofit Muslim Wellness Foundation, which provides mental health educational services to the community. For more information on the Physician Support Line please go to: https://www.physiciansupportline.com/

Methamphetamine is an extremely serious problem in the United States, and it remains one of the most commonly misused stimulant drugs in the world. There are severe psychological, and medical consequences from methamphetamine misuse and abuse. This poses a particular challenge for clinicians treating patients for mental health conditions that are comorbid with substance use disorder (SUD). This is especially challenging when there are also interactions that can alter or influence psychiatric medications used to treat these patients. Questions such as the following arise: Given the high comorbidity of SUD with ADHD, how often should you check drug screens, and what is the threshold for discontinuing the stimulants if tests come back positive? In this podcast episode, Dr. William Sauve’ addresses these concerns, and much more. He also employs strategies to improve communication with patients about being transparent when it comes to using substances. Optional CME credits / certificate instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE. Learning Objectives: After completing this educational activity, you should be better able to: Manage the challenges associated with psychiatric treatment of conditions comorbid with substance use disorder Integrate psychiatric drug interactions with methamphetamine use Assess treatments approaches for conditions associated with long-term use of methamphetamines Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.  Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.50 continuing education hour of pharmacotherapeutics.  Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.  Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.  Faculty Interviewer Andrew J. Cutler, MD   Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Alkermes, Allergan, Axsome, Biohaven, Intra-Cellular, Lundbeck, Novartis, Otsuka, Sage, Sunovion, Tris   Consultant/Advisor: Acadia, AiCure, Alfasigma, Alkermes, Allergan, Avanir, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Takeda, Teva, Tris Speakers Bureau: Acadia, Alkermes, Allergan, Avanir, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Takeda, Teva, Tris Faculty Interviewee William M. Sauvé, MD Regional Medical Director, Greenbrook TMS NeuroHealth Centers, Virginia Speakers Bureau: Avanir  Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.  The Planning Committee and Peer Reviewer have no financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.  Support: This activity is supported solely by the provider, NEI.  Released: June 8, 2020          CME credit expires: June 8, 2023

What is the prevalence of bipolar disorder in the pediatric population and does this change, depending on age? What are important tips for recognizing hypomania in children, and diagnosing children with mixed depression? In this episode, we address these questions and more with pediatric psychiatrist, Dr. Manpreet Singh.  Dr. Singh is Associate Professor of Psychiatry and Behavioral Sciences at Stanford University, and leads a program aimed to accelerate understanding and treatment in youth with or at high risk for developing lifelong mood disorders. She is the director of the Pediatric Mood Disorders Program and the Pediatric Emotion and Resilience Program at Stanford University. Dr. Singh earned her MD at Michigan State University and her MS at University of Michigan. She completed her combined residency training in Pediatrics, Psychiatry, and Child and Adolescent Psychiatry at Cincinnati Children’s Hospital Medical Center. After two years of T32 postdoctoral training at Stanford’s Center for Interdisciplinary Brain Sciences Research, she joined the faculty in 2009. Dr. Singh leads a multidisciplinary team that evaluates and treats youth with a spectrum of mood disorders as young as age 2 and well into their 20s. Her NIMH and industry funded studies examine mechanisms underlying mood disorders and apply cutting edge strategies to directly modulate the brain using transcranial magnetic stimulation and real time neurofeedback. She is also investigating the efficacy and safety of pharmacotherapies and psychotherapies, such as family focused psychotherapy and mindfulness meditation, to reduce mood symptoms and family stress. All of these areas of research aim to elucidate core mechanisms underlying mood disorders and how treatment early in life can pave the path to more adaptive outcomes. In her spare time, Dr. Singh enjoys traveling and hiking with her husband and three children, and avidly teaches Indian classical music. Her clinical handbook for the diagnosis and treatment of pediatric mood disorders can be found at the link below: https://appi.org/Products/Mood-Disorders/Clinical-Handbook-for-the-Diagnosis-and-Treatment?SearchText=clinical%20handboo&sku=37174